Mochida Pharmaceutical Co., Ltd.

Isis Pharmaceuticals, Inc.

Shoji Furusako

Kamon Shirakawa

Tsutomu Satoh

Yoshitaka Hosaka

Tetsushi Kawahara

Tomohiro Narumi

Tomokazu Matsusue

Motoyasu Honda

Katsuki Naitoh

Hiroshi Takayama

Yumi Hotta

Takashi Takeuchi

Masaki Nakamura

Jiro Hirose

Kazuyuki Nakayama

Shingo Sato

Chikateru Nozaki

Thomas W Bruice

Kevin P Anderson

Walter F Lima

Ronnie C Hanecak

Fukusaburo Hamada

Hiroshi Nakatake

Tsukasa Nishihara

Tatsuo Eto

Kazuya Hoshiko

Shinichi Furukawa

Sadao Mori

Yoshifumi Horisawa

Takeshi Kusuyama

Provided are a novel crosslinked alginic acid, a crosslinked alginic acid structure, etc., by performing a crosslinking reaction using alginic acid derivatives represented by formula (I) and formula (II). As a result, a novel crosslinked alginic acid, crosslinked alginic acid structure, etc., are provided.

Crosslinked alginic acid structure

There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic β cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

Polymer-coated crosslinked alginate gel fiber

The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.

Crosslinked alginic acid

The present invention provides: an alginic acid derivative having a photocrosslinking group represented by general formula (1) for a portion of a carboxyl group of alginic acids, and a photocrosslinking alginic acid structure which is produced using this alginic acid. Due to this configuration, a novel alginic acid derivative is provided. 

Photocrosslinkable alginic acid derivative

The present invention provides alginic acid derivatives having a group represented by general formula (I) or general formula (II) (the right side of the dashed line is excluded in each formula) at a portion of the carboxyl groups in an alginic acid. Novel alginic acid derivatives are thereby provided. 

Reactive alginic acid derivatives

A protein comprising (I) an anti-CDantibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Polynucleotide encoding anti-CD14 antibody fusion protein

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

Anti-platelet membrane glycoprotein VI monoclonal antibody

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof:

A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Anti-CD14 antibody fusion protein

There are provided a soluble CD14 antigen which is a novel in vivo protein useful as a marker for diagnosing sepsis and has the following characteristic features 1) to 3):

Soluble CD14 antigen

The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis.

Assay kit and antibody for human low molecular weight CD14

Methods for detecting human low molecular weight CD14

The present invention provides an antibody which specifically recognizes an epitope containing a part of a domain based on a finding that the domain ranging from the 269- to 315-positions of human CD14 represented by SEQ ID NO:1 is a site capable of interacting with another protein, an antibodies provided. This antibody can inhibit the interaction between human CD14 and another protein and thus suppress cell activation. And also, the present invention provides hybridomas producing the above antibody or its fragment; a peptide containing the amino acids in the domain as specified above; a method of constructing an antibody with the use of this peptide as an immunogen; and a method of screening a medicament for sepsis involving the step of bringing a test substance into contact with CD14 and TLR.

Growing community of inventors

Tokyo, Japan

Shoji Furusako